Tae-Beom Kim
Overview
Explore the profile of Tae-Beom Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westin S, Labrie M, Litton J, Blucher A, Fang Y, Vellano C, et al.
Clin Cancer Res
. 2021 Sep;
27(23):6354-6365.
PMID: 34518313
Purpose: On the basis of strong preclinical rationale, we sought to confirm recommended phase II dose (RP2D) for olaparib, a PARP inhibitor, combined with the AKT inhibitor capivasertib and assess...
2.
Akcakanat A, Zheng X, Cruz Pico C, Kim T, Chen K, Korkut A, et al.
Clin Cancer Res
. 2021 Mar;
27(11):3243-3252.
PMID: 33782032
Purpose: Metastatic breast cancer (MBC) is not curable and there is a growing interest in personalized therapy options. Here we report molecular profiling of MBC focusing on molecular evolution in...
3.
Veeranki O, Tong Z, Mejia A, Verma A, Katkhuda R, Bassett R, et al.
Dis Model Mech
. 2019 Nov;
12(12).
PMID: 31732509
Mouse models of gastroesophageal junction (GEJ) cancer strive to recapitulate the intratumoral heterogeneity and cellular crosstalk within patient tumors to improve clinical translation. GEJ cancers remain a therapeutic challenge due...
4.
Ruiz-Cordero R, Rao P, Li L, Qi Y, Atherton D, Peng B, et al.
Mod Pathol
. 2019 Jun;
32(11):1698-1707.
PMID: 31231128
Hybrid oncocytic/chromophobe tumor (HOCT) of the kidney represents a poorly understood clinicopathologic entity with pathologic features that overlap between benign renal oncocytoma (RO) and malignant chromophobe renal cell carcinoma (ChRCC)....
5.
Labrie M, Kim T, Ju Z, Lee S, Zhao W, Fang Y, et al.
Oncotarget
. 2019 Jun;
10(37):3533-3546.
PMID: 31191824
Poly (ADP-ribose) polymerase inhibitor (PARPi)-based combination therapies are demonstrating efficacy in patients, however, identifying the right combination for the right patient remains a critical challenge. Thus, it is urgent to...
6.
Fang Y, McGrail D, Sun C, Labrie M, Chen X, Zhang D, et al.
Cancer Cell
. 2019 Jun;
35(6):851-867.e7.
PMID: 31185210
We demonstrate that concurrent administration of poly(ADP-ribose) polymerase (PARP) and WEE1 inhibitors is effective in inhibiting tumor growth but poorly tolerated. Concurrent treatment with PARP and WEE1 inhibitors induces replication...
7.
Wang F, Zhang S, Kim T, Lin Y, Iqbal R, Wang Z, et al.
Nat Methods
. 2019 Apr;
16(5):401-404.
PMID: 30988467
Profiling of both the genome and the transcriptome promises a comprehensive, functional readout of a tissue sample, yet analytical approaches are required to translate the increased data dimensionality, heterogeneity and...
8.
Klebanov N, Lin W, Artomov M, Shaughnessy M, Njauw C, Bloom R, et al.
JAMA Dermatol
. 2019 Jan;
155(2):211-215.
PMID: 30601876
Importance: Shared gene variants in benign-malignant process pairs, such as BRAF mutations common to benign nevi and melanoma, are associated with differing phenotypic manifestations. Study of gene mechanisms underlying cherry...
9.
Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, et al.
JCO Precis Oncol
. 2018 Jul;
2018.
PMID: 30035249
Purpose: We sought to determine the significant genomic alterations in patients with metastatic breast cancer (MBC), and survival outcomes in common genotypes. Patients And Methods: High-depth next generation sequencing was...
10.
Wang Z, Ng K, Chen T, Kim T, Wang F, Shaw K, et al.
PLoS One
. 2018 May;
13(5):e0196939.
PMID: 29738578
Identification of cancer driver mutations is critical for advancing cancer research and personalized medicine. Due to inter-tumor genetic heterogeneity, many driver mutations occur at low frequencies, which make it challenging...